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Background: Over the past several years the incidence of cutaneous melanoma has rapidly increased. This tumor
develops often in-transit metastases that significantly reduce patient survival at 5 years. To improve prognosis and
quality of life in patients with melanoma metastases, a mini invasive procedure like electrochemotherapy (ECT) is
adopted to remove superficial tissue lesions. To detect the melanoma metastases, high frequency (HF) ultrasound (US)
is used. This technique, though, can be time-consuming and it needs an expert operator and a high performing
machine. Therefore, we asked whether the US could be replaced or integrated with other less time-consuming
techniques such as 18-FDG positron emission tomography/computed tomography (PET-CT) and telethermography (TT).
Methods: Fifteen patients (4 males and 11 females - age range: 63–91) affected whit advanced stage melanoma were
enrolled. They presented 52 in-transit metastases as detected by the three techniques used, HF-US, PET/CT and TT within
30 days before ECT.
Results: All the 52 lesions were detected by HF-US (100%), 24/52 were detected by PET-CT (42,6%) and 15/52 were
detected by TT (27,7%). PET-CT reported 3.7% false positives, while no false positive were reported by TT.
Conclusions: As US detected 100% lesions, compared to the other two techniques used, US, along with clinical
examination, has still to be considered as gold standard in the diagnosis of metastatic lesions. US, associated with an
exhaustive anamnesis and accurate clinical examination, cannot be replaced by either PET-CT or TT. When US performing
devices and experienced operators are not available, though, it is highly recommended to integrate US with at least one
of the other techniques. Under certain circumstances, as in the case of obese and non-collaborating patients or in patients
with lymphatic stasis, these techniques should be integrated to obtain exact in-transit metastases evaluation.
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ElectrochemotherapyIntroduction
Over the past several years the incidence of cutaneous
melanoma has rapidly increased (incidence ranging from
2 to 20%) with about 60,000 new cases diagnosed every
year in Europe [1-3]. Five-year survival rate varies in a
wide range (10-70%, depending on many variables) and* Correspondence: solivetti@ifo.it
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unless otherwise stated.it is reported to be much lower in patients with cutaneous
metastases [4-8]. Cutaneous metastases from melanoma
are very frequent and related to different risk factors and
clinical parameters of which the most relevant are high
thickness and number of mitoses, all determining tumor
stage and consequently different patient management
[9,10]. Clinically, these lesions could appear as solitary or
multiple and present a papule-like or nodule-like morph-
ology with possible ulceration as well as erysipeloid or ery-
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of life in patients with melanoma metastases, mini invasive
procedure like electrochemotherapy (ECT) [11,12] is
adopted to remove superficial tissue lesions. However, to
choose the correct therapeutical approach, an exact
localization of site, number and size of metastases as well
as their depth are necessary [12-15]. To this purpose, at
present, ultrasound (US) examination with high frequency
(HF) [16,17] probes is considered to be the best diagnostic
choice due to its high accuracy in detecting this kind of le-
sions. However, US has important limitations, such as pro-
longed execution time (not less than 30′-40′ for each limb
or body area) and being much dependent on the operator’s
skills, and the availability of a performing machine oper-
ated by an expert radiologist. Since we don’t have at the
moment the possibility to perform in the normal clinical
practice worldwide these specialized exams with the same
protocol, an expert operator and US machine, we have
probably to find a compromise among an acceptable sen-
sitivity, the time needed to perform the exams and the real
cost of these exams for the healthcare system. Therefore,
it is important to evaluate whether other available tech-
niques might have good sensitivity for detecting melan-
oma metastases in patients eligible for ECT, in order to
replace or integrate US with other less time-consuming
imaging techniques. In this respect, positron emission
tomography/computed tomography (PET-CT) and tele-
thermography (TT) can be considered useful to overcome
these limitations and to obtain adequate diagnostic results.
Therefore, the aim of this study was to compare US with
18-FDG PET-CT and TT in the detection of melanoma
metastases in a subgroup of patients with advanced stage
melanoma eligible for ECT.
Materials and methods
Ethics statement
This prospective single-centre, open-label study was ap-
proved by IFO-San Gallicano Institute review board and
followed the principles of the Declaration of Helsinki and
subsequent amendments. All participants provided written
informed consent before participating in the study.
Study population
We analyzed 52 lesions from 15 melanoma patients (age
ranging from 63 to 91 years) scheduled for ECT treatment
in the San Gallicano Institute, with HF-US, 18-FDG PET-
CT, and TT. The whole evaluation was completed in a
maximum of 30 days. All patients were followed up, as en-
visaged by standard protocols for melanoma, for at least
one year. Inclusion criteria were anamnestic presence of
melanoma and suspicious in-transit metastases. Before
ECT, a microhistologic or cytological examination was
performed on at least one of the nodules to be treated;
diagnostic suspicion in the patients of this cohort wasalways confirmed. All patients underwent to PET/CT also
for disease staging. Operators were blinded as for other
examinations.
High-frequency ultrasound (UF-US)
All HF-US examinations in our series were performed
with an Esaote MyLab 70 XVG (Genoa, Italy), using a
18 MHz linear probe, at times integrated by a 13 MHz
with specific setting. In selected cases, for very small and
superficial lesions, an Esaote MyLab One with 22 MHz
linear probe was utilized. Colour-Doppler US was per-
formed with multiple samplings from different areas of
the lesion thus allowing assessment of slow-flow condi-
tions. The following lesions characteristics were reported:
size, echogenicity, structure, margins, possible internal ne-
crosis and their depth, besides vascularization pattern (1 =
no vascularization, 2 = perilesional vascularization and 3 =
intralesional vascularization). On the basis of these param-
eters, an overall numerical value was attributed to suspi-
cious lesions between 0 and 3 (0 = benign lesion, 1 =
possibly benign lesion, 2 = probably malignant lesion and
3 =malignant lesion) [18-20].
Telethermography (TT)
Telethermography (TT) is a fast, unexpensive, non-
invasive, and reproducible technique, which enables to
transform into video images the infrared emissions of
the human body on the basis of any possible changes of
cutaneous temperature [21]. TT imaging gives the possi-
bility to visualize, in an homogenous hypothermic do-
main, the presence of hot spots suggestive of cutaneous
tumors [21-25]; in particular, this comes true in the
presence of a very high hyperthermic gradient, at times
with a specific pattern, as it is for melanoma (also
known as “thermal flame”). For this particular examin-
ation we utilized FLIR 3000 Thermocam™ (Flir Systems
Inc., Wilsonville, Or; USA) where the high spatial reso-
lution of this infrared camera, associated with thermo-
stimulation. This method utilizes a thermostimulator
enabling to standardize contact times and thermostimu-
lating temperatures. This makes it possible to detect
very low thermal gradients, sometimes <0,01°C, increas-
ing TT sensitivity, also in the case of low thermal gradi-
ents, as for small lesions (<0.5 cm), with consequent
low emittance from the little tumor mass [21-25].
Positron emission tomography/computed tomography
(PET/CT)
PET/CT analyses were performed with a Biograph Sensa-
tion 16 (Siemens Medical Solutions, Erlangen, Germany).
Following i.v. administration of specific drug such as 18-
fluoro-2-deoxy-D-glucose (18-FDG) (Iason GmbH, Graz,
Austria) at 10–15 mCi, diluted in 2–3 ml volume, the PET-
CT protocol envisages caudo-cranial imaging through low-
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is utilized, for optimization of supplied dose. PET examin-
ation is carried out from cranium to feet. In a whole-body
PET an average of 15 visual fields is obtained, with image
acquisition time of 2–3 minutes each. Coronal, sagittal and
transversal images are acquired with TrueX reconstruction
algorithm, 70 cm visual field and image matrix dimensions
128 × 128. CT images are reconstructed at a 512 × 512
pixel resolution while PET images with 168 × 168 pixel
matrix with final fusion of the images.
Electrochemotherapy (ECT)
Electrochemotherapy (ECT) utilizes high-frequency pulsed
electricity to increase membrane permeability of neoplastic
cells, thus creating micropores through which small drug
molecules can spread throughout the cells. Bleomycin and
cisplatin are the two more frequently utilized drugs [11].
The elevated in-cell drug concentration obtained with this
technique, enables to improve the chemiotherapeutical effi-
cacy of the agent which exerts its action locally at the elec-
tropermeabilization site.
Statistical analyses
Descriptive statistics were computed for all variables.
Continuous data were reported as the mean and cat-
egorical data were represented by frequencies and per-
centage values. Sensitivity (with the 95% confidence
interval – CI -) was estimated considering the US re-
sults as the gold standard.
Results
In our series, a total of 52 lesions were detected in 15 pa-
tients, as summarized in Table 1. Melanoma size varied
between 1.2 and 2.8 mm, while lesions’ size was between
1.7 and 25 mm. US enabled to detect 52 lesions (size 1.7-
25 mm, mean 7,1 mm; depth to epidermis 0–25 mm,
mean 6.5 mm); PET-CT detected 24 lesions (size 4–
25 mm, mean 10.8 mm; depth to epidermis 0–18 mm,
mean 5.8 mm - data confirmed by US -); TT identified 15
lesions (size 3.7-25 mm, mean 12.8 mm; depth to epider-
mis 0–18 mm, mean 4.7 mm- data confirmed by US -)
(Table 2). We found that 32 out of a total of 52 lesions
(61.5%) were visualized only by the instruments since they
were not clearly evident on clinical examination. US de-
tected all 52 lesions with 100% sensitivity; PET-CT de-
tected 24 lesions, with 46.2% (CI 95% 27.7/64.6)
sensitivity; PET-CT had 2 false positive (3.7% of the total if
related to the cohort in its entirety and 8.3% when referred
to the 24 patients diagnosed with this technique); TT de-
tected 15 lesions, with 28.8% (CI 95% 14.3/43.4) sensitiv-
ity, with no false positive results reported (Table 2). As
expected, sensitivity results of PET-CT and TT varied ac-
cording to lesions’ size, compared to US that reported
100% sensitivity at the smallest lesion’ size (Table 3).The vascularized lesions visualized by Doppler were 13
out of 15 melanomas (25%), larger than 7 mm and de-
tectable at PET-CT examination. In particular, TT
showed elevated sensitivity, 73.3% (CI 95% 30–100) for
lesions >7 mm and located at a relatively limited dis-
tance from the cutaneous plane; such sensitivity in-
creased with criostimulus as demonstrated by the fact that
out of the 15 lesions detected by TT only 4 were <7 mm
and all were superficial, located at a depth <7 mm from
the cutaneous plane.
ECT was well tolerated by the great majority of patients
enrolled in the study and the erithematous reaction, fre-
quently associated to treatment, usually vanished in a few
days even though it could sometimes form a sort of “scab”
on treated areas [12,15]. Involuntary muscle contractions
were reported in only 15% of patients recruited in this
study. The lesions treated with ECT showed very little
changes in the first 48 hours, while in the following few
weeks slowly became less well contoured and hypoecogenic
and with a reduction of their volume. The subcutaneous
adipose tissue became instead more inhomogeneous, while
superficial planes thickened and showed the tendency to in-
homogeneous fibrous tissue changes.
Discussion
The choice of a correct therapeutical approach for mel-
anoma needs an exact localization of site, number and
size of metastases as well as their depth [12-15]. HF-US
is confirmed to be the best imaging technique available
in the detection of melanoma in-transit-metastases
[18,21,25-31]. However, given some reported limitations
for HF-US, we wanted to compare HF-US technique
with PET-CT and TT, which still present good sensitivity
for detecting melanoma metastases in patients eligible
for ECT. The purpose was to evaluate whether it was
possible to replace or integrate HF-US with other less
time-consuming imaging techniques. We found that US
detected 100% of the in-transit metastases, compared to
the other two techniques utilized, confirming the greater
sensitivity of US in the diagnosis of subcutaneous lesions
(nodes and satellitosis).
In this study, in-transit metastases appeared as subcuta-
neous nodules, hypoechoic often with very low internal
echoes, because of poor melanin reflexion; margins were
not seldom irregular or polycyclic. The largest lesions
showed necrotic areas with anechoic appearance, however
due to their dimensions (usually they are <1 cm) nodules
appeared to be relatively homogeneous. Metastases were
single or multiple within a tumor, often located between
the primary lesion and the nodal basin draining that area.
The US, associated with clinical examination, has gener-
ally considered the diagnostic gold standard for melan-
oma. In a relatively recent study that enrolled 600 patients
with melanoma of clinically relevant thickness (>1 mm),
Table 1 Patients, melanoma and lesion characteristics
No. Sex Age (years) Year of diagnosis Melanoma thickness (mm) Lesions’ size (mm) Lesions’ depth (mm) Lesions’ site
1 M 80 2008 1.7
16 1.4 TRUNK
4 4 TRUNK
2 F 64 2010 1.7
15 7 LEG SX
25 2.5 LEG SX
3 F 71 2009 1.7
NEG NEG NEG
10 10 INGUINALE
4 F 75 2008 2.4 20 18 POPLITEAL
5 F 67 2009 1.2
4 7 POPLITEAL
NEG NEG NEG

















9 F 68 2009 1.7
9 2 FOREARM
3 10 LEFT LEG
3.2 4.5 LEFT LEG
4.2 8 LEFT LEG
4 3.5 LEFT LEG
4 2.5 LEFT LEG
4.6 1.5 LEFT LEG
2 1.6 LEFT LEG
4.3 25 LEFT LEG
10 M 80 2008 1.7
18 7 TRUNK
23 5 TRUNK
11 F 78 2010 11 3 RIGHT LEG
9 2 RIGHT LEG
12 F 91 20111 4 16 RIGHT LEG
13 F 83 2010
12 12 POPLITEAL CAVITY
5 5 RIGHT LEG
17 5 EXTERNAL MALLEOLUS
14 12 LEG
14 M 75 2010
6 7 LEFT LEG
4 4 LEFT LEG
2.5 3 LEFT THIGH
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Table 1 Patients, melanoma and lesion characteristics (Continued)
2.3 4 LEFT THIGH
2 4 LEFT THIGH
4 5 LEFT THIGH
3 7 LEFT THIGH
1.7 4 LEFT THIGH
3 5 LEFT THIGH
4.6 6 LEFT THIGH
2 3 LEFT THIGH
15 F 2011
7 4 LEFT MEDIAL MALLEULUS
4 5 LEFT LEG
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suspicious in-transit metastases were reported in 63 pa-
tients for a total amount of 95 lesions, all detected by US
that did not report false positive or false negative results
[18]. In addition, a recent study utilizing TT in the diagno-
sis of cutaneous metastases from melanoma on 74 patients
presenting 251 lesions showed 95% sensitivity and 100%
specificity for nodules >15 mm, and 58% sensitivity and
98% specificity for lesions between 5 and 15 mm [21].
These results though were less significant when the le-
sions extended to the deepest strata of teguments be-
yond 1.5 cm from epidermis [21], pointing at the
importance of the lesions’ size for the sensitivity of tech-
niques different than US. In agreement, here we con-
firmed the limit of TT in detecting small and/or deeply
located metastatic lesions.
In our study, lesions that exhibited internal vascular
signals at Doppler imaging were only 13 (24%); except
for 4 lesions that presented minimal vascularization, the
remnant 9 were >7 mm in diameter and all detected by
PET-CT. In the literature, vascular signal at Doppler are
reported to be detected in up to 70% of metastatic le-
sions, in particular the largest ones: such discrepancy
can be easily explained by the short mean diameter of
the lesions studied in our series (7 mm). Only 15 lesions
were detected with TT, with a 28.8% sensitivity.
Concerning PET-CT, our results seem to confirm their
validity only for vascularized and biologically active le-
sions, which usually correspond to high standard uptake
value (SUV). This technique is anyhow limited in differen-
tial diagnosis with venous ectasia. Moreover SUV values
do not seem to be directly linked to clinical significance ofTable 2 Lesions detected by HF-US, PET/CT, and TT
No lesions Size (mm) Depth to
epidermis (mm)
Sensitivity (%)
HF-US 52/52 1.7/25 0.25 100
PET-CT 24/52 4-25 0-18 46.2
TT 15/52 3.7-25 0-18 28.8the analysed sample, being then not always specific. When
carried out routinely, PET-CT does not allow to include
the interested area, i.e. the hand, and therefore sometimes
need a second scansion, with different protocols, thus cre-
ating further delay, cost rising, and limited availability,
despite the general value of PET-CT in tumor staging can-
not be denied. If more than one lesion of the surrounding
tissue is detected, only seldom is possible to detect their
exact number since they form a unique capturing mass.
PET-CT has not a high spatial resolution and, as con-
firmed in our series, the minimal detectable dimension of
the lesion must be at least 5 mm [30], as demostrated also
by our data. In the relevant literature few are the studies
which assessed the efficacy of FDG investigation in patients
with in-transit metastases. In a cohort of 64 patients - with
a total of 80 cutaneous lesions - comparing the diagnostic
possibilities of PET-CT with respect to whole- body MR,
the first shows higher sensitivity if compared to whole-
body magnetic resonance - 83% vs. 76% - but with a spe-
cificity of 65% [27]. Some Authors deem that coronal
orientation of MR can be more difficult to interpret than
axial plane if we are interested in detecting small subcuta-
neous metastases [27]. It is moreover highlighted the im-
portance of anamnesis along with a thorough clinical
examination [28,29], thus suggesting that further specific
studies on in-transit metastases are yet needed.
The small population enrolled in this study didn’t per-
mit a detailed statistical analyses and also the results ob-
tained did not permit to achieve our primary goal;
however we investigated a large number of lesions that
allowed us to elaborate some considerations and to say
that CT-PET and TT can integrate US information. HF-Table 3 Sensitivity values for PET-CT and TT according to
the lesions’ size; the sensitivity of US was 100%
Lesions PET-CT TT
Size (mm) <4 5-6 >7 <4 5-7 >7
Sensitivity (SD)
26% 29% 93% 9% 15% 73%
(5–47) (1–56) (44–100) (1–21) (1–37) (30–100)
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mitment of the operator, has relevant limitations in obese
or non-collaborating patients and in those with lymphatic
stasis. Moreover, differential diagnosis between still active
metastatic disease and outcomes of anamnestic ECT-
treated nodules can be quite demanding, in particular in
the absence of color or power Doppler signals. It is fur-
thermore impossible to exclude neoplastic residues inside
the treated tissue. This aspect has not been considered in
our study and such assumptions, which appear empirically
logical, should be at any rate confirmed by further studies.
Studies about the changes occurring in the morphological
aspect of the US detectable metastatic lesions, after ther-
apy, are not available: the only available data are relative to
the reduction of post-perfusion vascularization [32,33].
Both agree in underlining, also in the relatively short post-
operative period (about one week), a sharp reduction of
vascularization, associated with high ultrasound specificity
and sensitivity; such conclusions are in agreement with
our data but the small dimensions of the lesions in our
series envisage a low probability to detect a significant
vascularization with doppler. In our opinion all the tech-
niques we utilized has to be applicable early after treat-
ment because of the transitory modifications induced by
therapy. Furthermore, ultrasound has clear limits when
applied to areas already treated with ECT, also after a ra-
ther long time from treatment, but similar problems can
also be found with TT, since fibrotic tissue can interfere
with infrared transmission thus making the area appear as
“cold”. Similar phenomena are as well reported with TT in
deep lesions, especially in obese patients and those with
lymphatic stasis.
In conclusion, our preliminary results demonstrate
that HF-US cannot at the moment be replaced by other
available techniques in the diagnosis of in-transit me-
tastases, especially for the small ones. However, PET-
CT could have a real role in detecting deeper in transit
metastases and TT could have a role in detecting large
lesions and both could be useful in integrating the US
results. Further studies in a larger patient population
will be needed to confirm our results.
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